Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CGT003 (E2F Duplex Decoy)
DRUG
2 trials
Sponsors
Anesiva, Inc.
Conditions
Arterial Occlusive Diseases
Coronary Artery Disease
Graft Occlusion, Vascular
Hyperplasia
Ischemia
Peripheral Vascular Diseases
Phase 2
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
Completed
NCT00041925
Anesiva, Inc.
Arterial Occlusive Diseases, Graft Occlusion, Vascular, Hyperplasia +2
Start: 2001-11-30
End: 2004-11-30
Target: 1400
Updated: 2005-07-15
Phase 3
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
Completed
NCT00042081
Anesiva, Inc.
Coronary Artery Disease
Start: 2002-07-31
End: 2005-02-28
Target: 3000
Updated: 2006-05-05
Related Papers
Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes
Circulation
2016-01-11
87 citations
Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery
Circulation
2014-09-27
219 citations
Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery
JAMA Surgery
2014-06-19
85 citations
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
2005-11-01
457 citations